REGENXBIO Inc. (RGNX) — Analyst outlook / Analyst consensus target is. Based on 20 analyst ratings, the consensus is bullish — 1 Strong Buy, 13 Buy, 5 Hold, 1 Sell.
The consensus price target is $26.00 (low: $12.00, high: $45.00), representing an upside of 179.6% from the current price $9.30.
Analysts estimate Earnings Per Share (EPS) of $-4.73 and revenue of $0.09B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.59 vs est $-4.73 (beat +2.9%). 2025: actual $-3.76 vs est $-3.30 (missed -13.8%). Analyst accuracy: 92%.
RGNX Stock — 12-Month Price Forecast
$26.00
▲ +179.57% Upside
Average Price Target
Based on 20 Wall Street analysts offering 12-month price targets for REGENXBIO Inc., the average price target is $26.00, with a high forecast of $45.00, and a low forecast of $12.00.
The average price target represents a +179.57% change from the last price of $9.30.
Highest Price Target
$45.00
Average Price Target
$26.00
Lowest Price Target
$12.00
RGNX Analyst Ratings
Buy
Based on 20 analysts giving stock ratings to REGENXBIO Inc. in the past 3 months
EPS Estimates — RGNX
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$4.59
vs Est –$4.73
▲ 3.0% off
2025
Actual –$3.76
vs Est –$3.30
▼ 12.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — RGNX
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.083B
vs Est $0.087B
▼ 4.3% off
2025
Actual $0.170B
vs Est $0.185B
▼ 8.3% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
